We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 30

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients

Alleged Menendez Gift-Giver Loses Bid For Rehearing Of Medicare Overpayment Suit
  • Pietragallo Gordon Alfano Bosick & Raspanti LLP
  • USA
  • September 6 2016

In a prior post, we blogged about the Third Circuit's ruling that the political case against Senator Bob Menendez can proceed to trial. Now, in a

Deciphering Smoke Signals FDA’s New Tobacco Product Rules and Their Impact on the Cannabis Industry
  • Lane Powell PC
  • USA
  • August 5 2016

Dual-use cannabis consumption products and their off-label uses may cause those products to fall within the new FDA rules governing tobacco

Bipartisan bill gives FDA control over certain compounding entities: four key points
  • McGuireWoods LLP
  • USA
  • May 3 2013

Draft legislation introduced by the chairman and ranking member of the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) aims to

New complaint filed on behalf of CSP Technologies Inc.
  • McDermott Will & Emery
  • USA
  • May 18 2011

On May 17, 2011, a new Section 337 Complaint was filed on behalf of CSP Technologies Inc.

FDA grants genzyme's citizen petition requesting a second 30-month stay
  • Haynes and Boone LLP
  • USA
  • November 5 2010

On October 26, 2010, the FDA issued a letter decision addressing whether submission of a second PIV certification could give rise to a second, or superseding, 30-month stay.

CMS proposes to treat drug vial “overfills” as suspect free goods
  • Proskauer Rose LLP
  • USA
  • July 26 2010

CMS's annual summer tome, the proposed Physician Fee Schedule published this year on July 13, 2010, contains a significant new proposal that if adopted would affect the physicians, hospitals outpatient departments and others that bill for drugs and biologics under Medicare Part B.

FDA announces Safe Use initiative for drug products
  • Reed Smith LLP
  • USA
  • December 4 2009

The Food and Drug Administration (FDA) has announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.

Ohio S.B. 119: Ohio Senator seeks to mandate reporting of suspected drug dispensing errors and to criminalize failures to report
  • Baker & Hostetler LLP
  • USA
  • October 1 2009

Ohio Sen. Timothy Grendell, sponsor of Ohio’s pharmacy technician requirement nationally known as "Emily’s Law," introduced a bill that, if enacted, will change drastically the reporting of drug errors to and subsequent investigation process by Ohio Board of Pharmacy (Board).

FTC challenges proposed and completed acquisitions in the health care industry
  • Reed Smith LLP
  • USA
  • September 18 2009

The Federal Trade Commission ("FTC") has challenged some proposed and completed acquisitions of interest this summer, three of which have resulted in the abandonment of the proposed mergers.